Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16533109 | 0.84 | TRPA1 (0.39) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL19121837 | 0.84 | TRPA1 (0.39) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL8237013 | 0.83 | NFE2L2 (0.39) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL12447345 | 0.83 | TRPA1 (0.39) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL16953798 | 0.82 | CHRM1 (0.38) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL10155650 | 0.82 | PDE2A (0.44) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL19682798 | 0.82 | LMNA (0.38) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL30608020 | 0.82 | PDE2A (0.44) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL8251516 | 0.82 | TRPA1 (0.42) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL29337277 | 0.82 | PDE2A (0.44) | TRPA1LMNACHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400502-A2 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Shionogi & Co., Ltd (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023230026-A1 | PIPERIDINYL-METHYLPURINE BENZENES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4249474-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | SIMONEAU BRUNO | 2007-09-27 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007048779-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005103055-A1 | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | TRPA1 2379/4885LMNA 3039/4885CHRM1 4757/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885LMNA 170/4885CHRM1 3754/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885LMNA 170/4885CHRM1 3754/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | TRPA1 399/4885LMNA 3518/4885CHRM1 1232/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | TRPA1 399/4885LMNA 3518/4885CHRM1 1232/4885 |
| US-11793771-B2 | Immunomodulator compounds | IL2, IL2RA, C3AR1 | TRPA1 3038/4885LMNA 4728/4885CHRM1 81/4885 |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MAP4K5, MAP3K5, MAP4K2 | TRPA1 1945/4885LMNA 2315/4885CHRM1 2041/4885 |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | POLR2E, POLR2H, POLR2A | TRPA1 4537/4885LMNA 2603/4885CHRM1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.